Annual report pursuant to Section 13 and 15(d)

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)

v3.3.1.900
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)
 12 Months Ended
Dec. 31, 2015
USD ($)
Institution
License
Plan
$ / shares
shares
Dec. 31, 2014
USD ($)
$ / shares
shares
Cash and Cash Equivalents [Abstract]    
Highly liquid investments $ 0 $ 0
Number of financial institutions deposits are primarily maintained | Institution 2  
Allowance for doubtful accounts receivable $ 0 0
Goodwill [Abstract]    
Goodwill 32,466,000 0
Other Income [Abstract]    
Miscellaneous income $ 4,026,000 45,000
Number of years subject to statute of limitations by major tax jurisdiction 3 years  
Basic and diluted net loss per share [Abstract]    
Net loss allocable to common stockholders $ (14,526,000) $ (29,653,000)
Weighted average shares outstanding (in shares) | shares 27,597,434 1,942,905
Basic and diluted net loss per common share (in dollars per share) | $ / shares $ (0.53) $ (15.26)
Net loss allocable to common stockholders $ (14,526,000) $ (29,653,000)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 6,123,108 4,374,890
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of stock based compensation plans | Plan 2  
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 4,368,000 $ 1,305,000
Tax benefit 0 0
Stock-based compensation expense, net of tax $ 4,368,000 1,305,000
Gene Therapy [Member]    
Licensed Technology [Abstract]    
Number of patent family | License 1  
Period of amortization of license 20 years  
Plasma-based Therapeutics [Member]    
Licensed Technology [Abstract]    
License fee $ 1,000,000  
License fee payable $ 4,000,000  
Common stock shares in lieu of cash (in shares) | shares 1,096,151  
Period of amortization of license 11 years  
Regulatory approval milestone payment (in shares) | shares 513,375  
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful lives of property and equipment 3 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Estimated useful lives of property and equipment 5 years  
Research and Development [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 773,000 104,000
General and Administrative [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense 3,595,000 1,201,000
Operating Expense [Member]    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Total stock-based compensation expense $ 4,368,000 $ 1,305,000
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 3,799,024 4,164,756
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities not included in computation of diluted net income (loss) per common share (in shares) | shares 2,324,084 210,134